With a mean follow-up of @ years , the primary outcome occurred in @ of @ patients in the spironolactone group ( @ % ) and @ of @ patients in the placebo group ( @ % ) ( hazard ratio , @ ; @ % confidence interval -LSB- CI -RSB- , @ to @ ; P = @ ) .